UGT1A5 is a UDP-glucuronosyltransferase enzyme with limited catalytic activity toward phase II drug metabolism substrates. While initially characterized as enzymatically inactive, UGT1A5 exhibits low-level glucuronidation activity toward specific substrates like 1-hydroxypyrene and demonstrates N-glucuronidation capability 12. The enzyme is expressed in hepatic and intestinal tissues with considerable interindividual variability, and its expression is inducible by xenobiotic factors such as rifampicin 1. UGT1A5 mRNA levels increase significantly during childhood and adolescence, potentially driven by hormonal signaling 3. A common polymorphic variant (UGT1A5*8) displays ninefold higher activity due to optimized cofactor binding geometry from a Gly259Arg mutation 2. Interestingly, UGT1A5 is expressed in human platelets at higher levels than liver, with significantly elevated expression in smokers 4. In gastric cancer tissues, UGT1A5 expression is downregulated compared to normal stomach tissue, suggesting potential roles in cancer-related metabolic processes 5. The enzyme's restricted substrate specificity and regulatory properties distinguish it from other UGT1A isoforms.